This analysis has implicated several genes known to be involved in glioma or cancer progression (i.e., proliferation, invasion, metastasis) such as TGFB1II (39), FZD5 (40), EMR2 (41), ROMO1 (42), and BCL3 (43) which were significantly down-regulated with demeclocycline treatment in three BTIC lines (Figure 4). This evidence concerns the gene ADGRE2 and central nervous system cancer.